Assessing Acinetobacter baumannii virulence and treatment with a bacteriophage using zebrafish embryos.
Sofia NetoAna VieiraHugo OliveiraBegoña EspiñaPublished in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2023)
Acinetobacter baumannii is the leading bacteria causative of nosocomial infections, with high fatality rates, mostly due to their multi-resistance to antibiotics. The capsular polysaccharide (k-type) is a major virulence factor. Bacteriophages are viruses that specifically infect bacteria and have been used to control drug-resistant bacterial pathogens. In particular, A. baumannii phages can recognize specific capsules, from a diversity of >125 that exist. This high specificity demands the in vivo identification of the most virulent A. baumannii k-types that need to be targeted by phage therapy. Currently, the zebrafish embryo has particularly attained interest for in vivo infection modeling. In this study, an A. baumannii infection was successfully established, through the bath immersion of tail-injured zebrafish embryos, to study the virulence of eight capsule types (K1, K2, K9, K32, K38, K44, K45, and K67). The model revealed itself as capable of discerning the most virulent (K2, K9, K32, and K45), middle (K1, K38, and K67), and the less virulent (K44) strains. Additionally, the infection of the most virulent strains was controlled in vivo resorting to the same technique, with previously identified phages (K2, K9, K32, and K45 phages). Phage treatments were able to increase the average survival from 35.2% to up to 74.1% (K32 strain). All the phages performed equally well. Collectively, the results show the potential of the model to not only evaluate virulence of bacteria such as A. baumannii but also assess novel treatments' effectiveness.
Keyphrases
- acinetobacter baumannii
- pseudomonas aeruginosa
- drug resistant
- escherichia coli
- multidrug resistant
- biofilm formation
- cystic fibrosis
- antimicrobial resistance
- staphylococcus aureus
- gram negative
- mesenchymal stem cells
- drug delivery
- stem cells
- pregnant women
- human health
- risk assessment
- cancer therapy
- klebsiella pneumoniae
- replacement therapy
- genetic diversity